Psychedelic Stocks Explode 38% in a Single Day After Trump Signs Executive Order — Here’s What Investors Are Buying

On April 18, 2026, President Donald Trump signed a landmark executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” and Wall Street responded with one of the most dramatic single-day surges the mental health biotech sector has ever seen. Compass Pathways (CMPS) alone closed up more than 42% on April 20, making it one of the sector’s strongest one-day performances on record, while the broader psychedelic investment universe lit up from coast to coast.

For investors who have been quietly watching this space, the moment they had been waiting for finally arrived. For everyone else, the question is urgent and obvious: what exactly is happening, why does it matter, and which stocks are investors actually buying right now?

---

What Trump’s Executive Order Actually Says

Before you chase a ticker, you need to understand what moved the market. The executive order signed Saturday, April 18 directs multiple federal agencies — including the FDA, DEA, HHS, and the Department of Veterans Affairs — to accelerate both the research and patient access pipeline for psychedelic-based therapies.

The specific language in the order sets the tone clearly. “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America,” President Trump wrote.

Among the key provisions:

• The FDA is directed to provide a new class of “national priority vouchers” to psychedelic medicines classified as potential breakthroughs for serious conditions, significantly speeding up the regulatory review timeline
• The DEA is ordered to establish a framework allowing eligible patients to access investigational psychedelic drugs currently under regulatory scrutiny, via the Right to Try Act
• ARPA-H (the Advanced Research Projects Agency for Health) is instructed to allocate at least $50 million from existing federal funds to support state-level psychedelic research programs
• Ibogaine, a psychoactive compound derived from shrubs native to Central Africa, is explicitly named as a priority treatment, especially for veterans dealing with PTSD and opioid use disorder

The signing ceremony itself sent a powerful cultural signal. It included podcast icon Joe Rogan and HHS Secretary Robert F. Kennedy Jr., both prominent advocates of responsible psychedelic medicine. That kind of visibility matters in today’s market — it tells retail and institutional investors alike that this is not a fringe policy; it is a mainstream White House priority.

---

Why This Was a Regulatory Watershed Moment

To appreciate the magnitude of this executive order, you need a quick history lesson on psychedelic medicine in the United States. For decades, substances like psilocybin, MDMA, ibogaine, and ketamine-adjacent compounds sat in legal and regulatory limbo — classified as Schedule I drugs with “no accepted medical use,” even as clinical trials at Johns Hopkins, NYU, and UCSF consistently showed profound results for depression, PTSD, and addiction.

The FDA’s 2024 rejection of MDMA-assisted therapy for PTSD was widely seen as a setback, raising doubts about the regulatory appetite for psychedelic approvals. But Compass Pathways’ successful Phase 3 trial results for its COMP360 psilocybin therapy in February 2026 shifted the momentum dramatically, and as of April 2026, Polymarket’s prediction market puts the probability of at least one FDA psychedelic approval before year-end at 65%.

What Trump’s order does is remove friction at every layer of the federal bureaucracy simultaneously. Jefferies analyst Andrew Tsai, one of Wall Street’s most closely followed voices on the psychedelic sector, called the order “an official stamp of validation to the class” and evidence that the FDA, HHS, and the White House plan to support psychedelics in “real” and “actionable” ways. He added that with multiple executive branches now aligned, investor confidence should rise substantially as the sector approaches potential approvals between 2027 and 2030.

RBC Capital Markets analyst Brian Abrahams was equally direct, stating the executive order “should shave additional months off of FDA review and accessibility and accelerate potential revenue generation.”

---

The Stocks That Exploded — And Why Investors Are Buying Them

Let me break down the specific companies that saw the biggest moves on April 20, 2026, and what makes each one worth understanding before you make any investment decision.

Compass Pathways (NASDAQ: CMPS)

This is the marquee name in the psychedelic stock space, and for good reason. CMPS stock closed up 42.3% on April 20, making it the single biggest gainer in the sector. By some intraday measures, shares touched gains exceeding 50% before settling.

Why Compass? The company’s flagship drug candidate, COMP360, is a proprietary form of synthetic psilocybin being developed for treatment-resistant depression (TRD). After reporting strong Phase 3 data in early 2026, the company is now on track to submit a rolling New Drug Application to the FDA in late 2026, with a potential U.S. commercial launch targeted for late 2026 or 2027. The executive order’s “national priority voucher” mechanism could shave months off that review timeline.

From a technical and fundamental standpoint, the stock had been trading in the mid-$5 range through late March 2026, then surged from a $5.77 close on April 13 to $9.35 on April 20 — approximately a 60% move in a single week driven by this policy catalyst. CMPS has become a high-beta trading vehicle, meaning it moves faster and harder than the broader market on news events, which is both an opportunity and a risk.

AtaiBeckley (NASDAQ: ATAI)

AtaiBeckley, a venture platform that holds stakes in a diversified portfolio of psychedelic drug developers, closed up 22.2% on April 20 according to Morningstar, with some reports citing intraday gains of over 33%. ATAI is often treated as a bellwether for the group — it gives investors broad exposure to the psychedelic biotech pipeline without needing to pick a single winner.

The company’s exposure to psychedelic-based programs across multiple mental health indications means it is a direct beneficiary when U.S. policy signals become more supportive, even if no single ATAI program changes overnight. For investors who want sector-level exposure rather than single-stock risk, ATAI functions almost like an internally managed psychedelic fund.

GH Research (NASDAQ: GHRS)

GH Research focuses on the development of 5-MeO-DMT, a compound with a notably fast onset and short duration compared to psilocybin, making it attractive for clinical settings. Shares rose 16.9% to 20.3% on April 20, depending on the measure used. The company is advancing its GH001 candidate for treatment-resistant depression, and analysts view it as one of the better-positioned companies if the FDA accelerates breakthrough therapy reviews, which the executive order directly encourages.

Definium Therapeutics (NASDAQ: DFTX)

Definium is a smaller, higher-risk player, but it attracted significant attention this week. Its flagship candidate, DT120, is in Phase 3 trials for major depressive disorder (MDD) and generalized anxiety disorder (GAD), while a second candidate, DT402, targets autism spectrum disorder in Phase 2 trials. Shares were up between 2.4% and 8.5% on April 20 after pulling back sharply from larger intraday gains. The volatility reflects both the excitement and the uncertainty around a smaller company with a less mature pipeline.

Helus Pharma (NASDAQ: HELP)

This smaller biotech saw a 17% gain on April 20, with a market cap in the range of $273 million. Helus focuses on developing neuroactive compounds to treat depression and anxiety, and while it is further from commercialization than Compass or GH Research, the sector-wide tide lifted it meaningfully.

Cybin and Enveric BioSciences

Cybin’s U.S.-listed shares rose approximately 15%, while Enveric BioSciences gained around 5% to 7% in premarket and sustained portions of those gains through the session. Both companies are in earlier stages of development but carry significant upside if the regulatory environment continues to open.

---

The ETF Option: AdvisorShares Psychedelics ETF

For investors who don’t want single-stock exposure, the AdvisorShares Psychedelics ETF gained approximately 12% on the same day. This fund provides a diversified basket of psychedelic-adjacent biotech stocks and is one of the few ETF vehicles in the space. If you believe in the long-term thesis but are uncomfortable with the volatility of individual names, this is a reasonable entry point worth examining.

---

The Ibogaine Story: Veterans, Opioids, and Political Momentum

One of the most important threads running through the executive order is ibogaine, and understanding it is essential for any investor in this space. Ibogaine is a naturally occurring psychoactive alkaloid found in the Tabernanthe iboga shrub, native to Central Africa. It has been used for decades in addiction medicine outside the United States — particularly in Mexico and Canada — and has shown remarkable early results for opioid use disorder and veteran PTSD.

Texas passed a law in 2025 allocating $50 million to study ibogaine for mental health conditions, and that state program is the most immediate beneficiary of the federal ARPA-H funding directed by Trump’s executive order. The bipartisan coalition behind ibogaine research includes veterans’ advocacy groups, Republican lawmakers, and figures across the political spectrum who see it as a lifeline for the approximately 20 veterans who die by suicide every single day in America.

Joe Rogan’s presence at the White House signing ceremony is not just a cultural footnote. It reflects a grassroots movement that has been building for years in veteran communities, and Trump’s order effectively brings that movement into official federal policy. This political durability is exactly the kind of structural tailwind that long-term investors in biotech want to see before committing capital.

---

What Analysts Are Saying: Risk and Reward

It would be irresponsible to write about a 38% to 50% single-day surge without addressing the risks clearly. Here is what the serious money is saying:

On the bullish side, Jefferies’ Andrew Tsai views the order as transformative for investor sentiment, noting that with the FDA, HHS, VA, and the White House now aligned, approval timelines that once seemed years away could compress dramatically. The addition of “national priority vouchers” as a formal regulatory mechanism is a concrete, structural change that should persist beyond any single administration’s tenure.

On the cautious side, biotech analysts consistently point out that many of these companies are pre-revenue, and some are pre-Phase 3. An executive order accelerates timelines but does not guarantee positive clinical outcomes. The 2024 MDMA rejection by the FDA — which came after years of promising Phase 2 data — is a stark reminder that even politically favorable environments cannot override clinical data.

Short sellers and skeptics will also note that these stocks have moved dramatically in short periods before, only to retreat when headlines faded. CMPS, for example, traded in the mid-$5 range just two weeks before this order. A disciplined investor considers both the entry price and the probability-weighted outcome of the clinical pipeline, not just the policy catalyst.

---

The Bigger Picture: America’s Mental Health Crisis as Investment Thesis

Step back from the day-to-day price action, and you see a profoundly important investment thesis taking shape. The United States faces a mental health crisis of historic proportions. More than 57 million Americans live with a mental illness. Treatment-resistant depression affects roughly one-third of the 21 million Americans diagnosed with major depressive disorder. Suicide claims more than 47,000 American lives annually. Opioid overdoses killed more than 80,000 Americans in 2023 alone.

Traditional antidepressants and psychiatric medications have remained largely unchanged in their mechanism of action for decades. Psychedelic-assisted therapies offer a fundamentally different approach — one that, in clinical trials, has produced lasting improvements in as few as one to three sessions. Johnson & Johnson’s esketamine (Spravato), a ketamine-adjacent treatment approved in 2019, surpassed $1 billion in annual revenue in 2024, proving that psychedelic-adjacent treatments can achieve commercial scale.

Trump’s executive order is not happening in a vacuum. It is the culmination of years of bipartisan groundwork, clinical research, and shifting cultural attitudes about mental health. The fact that the president signed this order in a ceremony with RFK Jr. and Joe Rogan — two figures with enormous reach across very different American demographics — signals that the political consensus behind psychedelic medicine has reached critical mass.

---

What Should Investors Actually Do Now?

If you are an investor evaluating this sector for the first time, here are the fundamental considerations:

• Understand the pipeline stage. Compass Pathways is the closest to a commercial product with its COMP360 NDA submission expected in late 2026. That proximity to revenue makes it the lowest-risk pure-play in the group, though “low risk” in psychedelic biotech is a relative term.
• Consider position sizing carefully. These are small-cap and micro-cap biotechs. Single-digit price stocks can double or go to zero based on trial results. No more than a small allocation of a diversified portfolio should go into any single name.
• Watch the FDA’s response to the voucher mechanism. The “national priority voucher” directed by the executive order is novel and potentially powerful, but its legal durability and practical implementation will take months to clarify. Follow regulatory filings closely.
• Track the DEA scheduling decisions. The executive order directs the DEA to establish a Right to Try pathway for investigational psychedelics. If the DEA moves to reclassify ibogaine or psilocybin — even partially — it would be a massive catalyst independent of the FDA timeline.
• The ETF provides a safer entry. If single-stock risk feels uncomfortable, the AdvisorShares Psychedelics ETF gives you diversified exposure with less concentration risk.

---

The Bottom Line

April 18, 2026 may well be remembered as the day psychedelic medicine became official U.S. policy. When the president of the United States signs an executive order directing the FDA, DEA, HHS, and VA to collectively accelerate an entire class of treatments — and allocates $50 million in federal research funding to back it up — the market is right to take notice.

The surge in Compass Pathways, AtaiBeckley, GH Research, and their peers is not irrational exuberance. It reflects a genuine reassessment of risk-adjusted timelines for a group of companies whose drugs address some of the most intractable health crises in America. The path from here to commercialization still has clinical, regulatory, and manufacturing hurdles. But for the first time in modern American history, the full weight of the federal government is aligned behind getting these treatments to patients.

For investors, that is not just a trading catalyst. It is the beginning of a structural shift in one of the most important sectors in American healthcare.

---

This article is for informational purposes only and does not constitute financial advice. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions.